{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:23:47Z","timestamp":1793258627968,"version":"4.5.0"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.blre.2022.100971","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T17:53:19Z","timestamp":1652723599000},"page":"100971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML"],"prefix":"10.1016","volume":"56","author":[{"given":"Rares","family":"Drula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Iluta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gulei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Iuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ghiaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca Dana","family":"Buzoianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ciechanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2022.100971_bb0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrm1552","article-title":"Proteolysis: from the lysosome to ubiquitin and the proteasome","volume":"6","author":"Ciechanover","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nrm3982","article-title":"The unravelling of the ubiquitin system","volume":"16","author":"Ciechanover","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0015","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bbamcr.2013.07.007","article-title":"The complexity of recognition of ubiquitinated substrates by the 26S proteasome","volume":"1843","author":"Ciechanover","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.blre.2022.100971_bb0020","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/anie.201205656","article-title":"The lysine48-based polyubiquitin chain proteasomal signal: not a single child anymore","volume":"52","author":"Kravtsova-Ivantsiv","year":"2013","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.blre.2022.100971_bb0025","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.tibs.2017.09.002","article-title":"The ubiquitin code in the ubiquitin-proteasome system and autophagy","volume":"42","author":"Kwon","year":"2017","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.blre.2022.100971_bb0030","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbcan.2017.09.002","article-title":"The roles of ubiquitin modifying enzymes in neoplastic disease","volume":"1868","author":"Kumari","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.blre.2022.100971_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/bies.201700027","article-title":"Monoubiquitination joins polyubiquitination as an esteemed proteasomal targeting signal","volume":"39","author":"Livneh","year":"2017","journal-title":"BioEssays News Rev Mol Cell Dev Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0040","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.biocel.2016.07.019","article-title":"The ubiquitin-proteasome system and autophagy: coordinated and independent activities","volume":"79","author":"Cohen-Kaplan","year":"2016","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0045","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1177\/1535370216651732","article-title":"Post-translational modification profiling - A novel tool for mapping the protein modification landscape in cancer","volume":"241","author":"Eisenberg-Lerner","year":"2016","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.blre.2022.100971_bb0050","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s13238-017-0486-3","article-title":"The role of ubiquitination and deubiquitination in the regulation of cell junctions","volume":"9","author":"Cai","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.blre.2022.100971_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/febs.15118","article-title":"Control of the inflammasome by the ubiquitin system","volume":"287","author":"Lopez-Castejon","year":"2020","journal-title":"FEBS J"},{"key":"10.1016\/j.blre.2022.100971_bb0065","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/nm.3739","article-title":"Ubiquitination in disease pathogenesis and treatment","volume":"20","author":"Popovic","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2022.100971_bb0075","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2022.100971_bb0080","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0085","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.blre.2022.100971_bb0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bbrc.2020.05.186","article-title":"CRL4DCAF8 and USP11 oppositely regulate the stability of myeloid leukemia factors (MLFs)","volume":"529","author":"Huang","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.blre.2022.100971_bb0095","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1242\/jcs.093567","article-title":"Non-canonical ubiquitin-based signals for proteasomal degradation","volume":"125","author":"Kravtsova-Ivantsiv","year":"2012","journal-title":"J Cell Sci"},{"key":"10.1016\/j.blre.2022.100971_bb0100","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrm3173","article-title":"The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation","volume":"12","author":"Weissman","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0105","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/cdd.2011.16","article-title":"Ubiquitination of E3 ligases: self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms","volume":"18","author":"de Bie","year":"2011","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.blre.2022.100971_bb0110","first-page":"30","article-title":"The role of deubiquitinating enzymes in gastric cancer","volume":"19","author":"Sun","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.blre.2022.100971_bb0115","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.7150\/thno.36503","article-title":"Deubiquitinase USP28 inhibits ubiquitin ligase KLHL2-mediated uridine-cytidine kinase 1 degradation and confers sensitivity to 5\u2032-azacytidine-resistant human leukemia cells","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.blre.2022.100971_bb0120","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/10428194.2021.2002321","article-title":"Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy","volume":"63","author":"Miyamoto","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2022.100971_bb0125","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1158\/0008-5472.CAN-14-1211","article-title":"Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer","volume":"74","author":"Pal","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2022.100971_bb0130","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-16-2692","article-title":"Blockade of deubiquitylating enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells","volume":"23","author":"Das","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2022.100971_bb0135","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.1073\/pnas.1517041113","article-title":"The histone H2A deubiquitinase Usp16 regulates hematopoiesis and hematopoietic stem cell function","volume":"113","author":"Gu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2022.100971_bb0140","doi-asserted-by":"crossref","first-page":"48391","DOI":"10.18632\/oncotarget.10268","article-title":"Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma","volume":"7","author":"Wei","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2022.100971_bb0145","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.molcel.2005.01.008","article-title":"The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway","volume":"17","author":"Nijman","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.blre.2022.100971_bb0150","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41467-019-10408-5","article-title":"DNA requirement in FANCD2 deubiquitination by USP1-UAF1-RAD51AP1 in the Fanconi anemia DNA damage response","volume":"10","author":"Liang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2022.100971_bb0155","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41594-021-00576-8","article-title":"Structural basis of FANCD2 deubiquitination by USP1-UAF1","volume":"28","author":"Rennie","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0160","doi-asserted-by":"crossref","first-page":"8186","DOI":"10.1074\/jbc.RA120.013714","article-title":"The DNA-binding activity of USP1-associated factor 1 is required for efficient RAD51-mediated homologous DNA pairing and homology-directed DNA repair","volume":"295","author":"Liang","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2022.100971_bb0165","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202050133","article-title":"Differential functions of FANCI and FANCD2 ubiquitination stabilize ID2 complex on DNA","volume":"21","author":"Rennie","year":"2020","journal-title":"EMBO Rep"},{"key":"10.1016\/j.blre.2022.100971_bb0170","article-title":"Mechanism, specificity, and function of FANCD2-FANCI ubiquitination and deubiquitination","author":"Lemonidis","year":"2021","journal-title":"FEBS J"},{"key":"10.1016\/j.blre.2022.100971_bb0175","first-page":"2117","article-title":"High expression of ID1 facilitates metastasis in human osteosarcoma by regulating the sensitivity of anoikis via PI3K\/AKT depended suppression of the intrinsic apoptotic signaling pathway","volume":"11","author":"Zhao","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.blre.2022.100971_bb0180","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3324\/haematol.2013.096438","article-title":"Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K\/Akt pathway despite high PTEN protein levels","volume":"99","author":"Gomes","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2022.100971_bb0185","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S1470-2045(10)70114-5","article-title":"Glucocorticoid use in acute lymphoblastic leukaemia","volume":"11","author":"Inaba","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2022.100971_bb0190","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/mc.23330","article-title":"ALKBH5-mediated m6A-demethylation of USP1 regulated T-cell acute lymphoblastic leukemia cell glucocorticoid resistance by Aurora B","volume":"60","author":"Gong","year":"2021","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.blre.2022.100971_bb0195","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cell.2009.12.032","article-title":"USP10 regulates p53 localization and stability by deubiquitinating p53","volume":"140","author":"Yuan","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.blre.2022.100971_bb0200","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.stemcr.2016.11.003","article-title":"USP10 is an essential deubiquitinase for hematopoiesis and inhibits apoptosis of long-term hematopoietic stem cells","volume":"7","author":"Higuchi","year":"2016","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.blre.2022.100971_bb0205","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/nchembio.2486","article-title":"Inhibition of USP10 induces degradation of oncogenic FLT3","volume":"13","author":"Weisberg","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0210","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41416-020-0731-z","article-title":"Inhibition of the deubiquitinase USP10 induces degradation of SYK","volume":"122","author":"Yang","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2022.100971_bb0215","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ccr.2014.01.022","article-title":"SYK is a critical regulator of FLT3 in acute myeloid leukemia","volume":"25","author":"Puissant","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2022.100971_bb0220","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0225","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41421-019-0092-z","article-title":"USP10 modulates the SKP2\/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia","volume":"5","author":"Liao","year":"2019","journal-title":"Cell Discov"},{"key":"10.1016\/j.blre.2022.100971_bb0230","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1038\/s41388-020-1253-0","article-title":"Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells","volume":"39","author":"Shibata","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2022.100971_bb0235","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1038\/ncomms4818","article-title":"The histone H2A deubiquitinase Usp16 regulates embryonic stem cell gene expression and lineage commitment","volume":"5","author":"Yang","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2022.100971_bb0240","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1172\/JCI123801","article-title":"USP16-mediated deubiquitination of calcineurin A controls peripheral T cell maintenance","volume":"129","author":"Zhang","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2022.100971_bb0250","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1182\/blood.V112.11.4481.4481","article-title":"Deregulated expression of ubiquitin-specific peptidase genes in myeloid leukemia","volume":"112","author":"Giguere","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0260","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/sj.emboj.7601567","article-title":"The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2","volume":"26","author":"Stevenson","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.blre.2022.100971_bb0265","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1038\/s41375-019-0451-7","article-title":"Human MLL\/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions","volume":"33","author":"Meyer","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100971_bb0270","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/gcc.22842","article-title":"Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia","volume":"59","author":"Blackburn","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.blre.2022.100971_bb0275","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.3390\/cancers13123079","article-title":"Targeting the ubiquitin-proteasome system for cancer therapeutics by small-molecule inhibitors","volume":"13","author":"LaPlante","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2022.100971_bb0280","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-030-38266-7_6","article-title":"Resistance to the proteasome inhibitors: lessons from multiple myeloma and mantle cell lymphoma","volume":"1233","author":"Gonzalez-Santamarta","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.802832","article-title":"The role of proteasome inhibitors in treating acute lymphoblastic Leukaemia","volume":"11","author":"Sin","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2022.100971_bb0290","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2022.100971_bb0295","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2022.100971_bb0300","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood-2013-05-500033","article-title":"A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance","volume":"123","author":"Tian","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0305","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.blre.2022.100971_bb0310","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment. J. Hematol. Oncol","volume":"13","author":"Duan","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2022.100971_bb0315","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41467-020-20259-0","article-title":"Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem\/progenitor cells in chronic myelogenous leukemia","volume":"12","author":"Lei","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2022.100971_bb0320","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.3390\/ijms22094546","article-title":"Advances in the development ubiquitin-specific peptidase (USP) inhibitors","volume":"22","author":"Chen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2022.100971_bb0325","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s10637-020-00915-4","article-title":"Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and\/or refractory multiple myeloma","volume":"38","author":"Rowinsky","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.blre.2022.100971_bb0330","doi-asserted-by":"crossref","first-page":"2913124","DOI":"10.1155\/2018\/2913124","article-title":"Bortezomib-induced pulmonary toxicity: A case report and review of literature","volume":"2018","author":"Kharel","year":"2018","journal-title":"Case Rep Med"},{"key":"10.1016\/j.blre.2022.100971_bb0335","first-page":"81","article-title":"FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML","volume":"12","author":"Weisberg","year":"2009","journal-title":"Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother"},{"key":"10.1016\/j.blre.2022.100971_bb0340","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41401-020-0455-x","article-title":"Wu-5, a novel USP10 inhibitor, enhances crenolanib-induced FLT3-ITD-positive AML cell death via inhibiting FLT3 and AMPK pathways","volume":"42","author":"Yu","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.blre.2022.100971_bb0345","doi-asserted-by":"crossref","first-page":"32885","DOI":"10.18632\/oncotarget.25972","article-title":"Combination of ATO with FLT3 TKIs eliminates FLT3\/ITD+ leukemia cells through reduced expression of FLT3","volume":"9","author":"Nagai","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2022.100971_bb0350","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1038\/onc.2008.175","article-title":"Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo","volume":"27","author":"Suh","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.blre.2022.100971_bb0360","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1182\/blood-2009-05-223115","article-title":"High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia","volume":"114","author":"Tang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0365","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molmed.2004.06.008","article-title":"Id genes and proteins as promising targets in cancer therapy","volume":"10","author":"Fong","year":"2004","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.blre.2022.100971_bb0370","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1158\/1535-7163.MCT-13-0103-T","article-title":"Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells","volume":"12","author":"Mistry","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2022.100971_bb0375","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7150\/ijms.47597","article-title":"Inhibition of USP1 induces apoptosis via ID1\/AKT pathway in B-cell acute lymphoblastic leukemia cells","volume":"18","author":"Kuang","year":"2021","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.blre.2022.100971_bb0380","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41375-020-0878-x","article-title":"Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy","volume":"35","author":"Cartel","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100971_bb0385","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood-2012-08-451666","article-title":"Nonredundant and locus-specific gene repression functions of PRC1 paralog family members in human hematopoietic stem\/progenitor cells","volume":"121","author":"van den Boom","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0390","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature01572","article-title":"Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells","volume":"423","author":"Lessard","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.blre.2022.100971_bb0395","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.molcel.2013.02.013","article-title":"Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put","volume":"49","author":"Simon","year":"2013","journal-title":"Mol Cell"},{"key":"10.1016\/j.blre.2022.100971_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102435","article-title":"The USP7-TRIM27 axis mediates non-canonical PRC1.1 function and is a druggable target in leukemia","volume":"24","author":"Maat","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.blre.2022.100971_bb0405","doi-asserted-by":"crossref","first-page":"E1175","DOI":"10.3390\/jcm8081175","article-title":"Approach to the adult acute lymphoblastic leukemia patient","volume":"8","author":"Sas","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2022.100971_bb0410","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/1078-0432.CCR-18-1740","article-title":"USP7 cooperates with NOTCH1 to drive the oncogenic transcriptional program in T-cell leukemia","volume":"25","author":"Jin","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2022.100971_bb0415","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors","volume":"43","author":"Wiesner","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2022.100971_bb0420","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.blre.2022.100971_bb0425","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2022.100971_bb0430","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Abdel-Rahman","year":"2011","journal-title":"J Med Genet"},{"key":"10.1016\/j.blre.2022.100971_bb0435","series-title":"GeneReviews\u00ae","article-title":"BAP1 Tumor predisposition syndrome","author":"Pilarski","year":"1993"},{"key":"10.1016\/j.blre.2022.100971_bb0440","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1126\/science.1221711","article-title":"Loss of the tumor suppressor BAP1 causes myeloid transformation","volume":"337","author":"Dey","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.blre.2022.100971_bb0445","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00018-019-03084-7","article-title":"The role of ASXL1 in hematopoiesis and myeloid malignancies","volume":"76","author":"Asada","year":"2019","journal-title":"Cell Mol Life Sci CMLS"},{"key":"10.1016\/j.blre.2022.100971_bb0455","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s43018-021-00199-4","article-title":"Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia","volume":"2","author":"Wang","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.blre.2022.100971_bb0460","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1038\/s41467-018-05085-9","article-title":"Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis","volume":"9","author":"Asada","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2022.100971_bb0465","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.canlet.2021.06.019","article-title":"Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells","volume":"519","author":"Bai","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.blre.2022.100971_bb0470","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0149-2918(00)88289-2","article-title":"S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide","volume":"21","author":"Zeldis","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.blre.2022.100971_bb0475","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/8466","article-title":"Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity","volume":"5","author":"Parman","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2022.100971_bb0480","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","article-title":"The evolution of thalidomide and its IMiD derivatives as anticancer agents","volume":"4","author":"Bartlett","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.blre.2022.100971_bb0485","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.100971_bb0490","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0495","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.blre.2022.100971_bb0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2021.07.031","article-title":"Myelodysplastic syndromes: A new decade","volume":"22","author":"Volpe","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2022.100971_bb0515","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/17474086.2022.2029698","article-title":"How low risk are low risk myelodysplastic syndromes?","volume":"15","author":"DeZern","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2022.100971_bb0520","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/hematology.2021000277","article-title":"Lower risk but high risk","volume":"2021","author":"DeZern","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2022.100971_bb0530","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00277-014-2022-3","article-title":"Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide","volume":"93","author":"Gaballa","year":"2014","journal-title":"Ann Hematol"},{"issue":"Suppl. 3","key":"10.1016\/j.blre.2022.100971_bb0535","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.3816\/CLM.2009.s.028","article-title":"Lenalidomide\u2014a transforming therapeutic agent in myelodysplastic syndromes","volume":"9","author":"List","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.blre.2022.100971_bb0540","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2015-04-640128","article-title":"Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion","volume":"127","author":"Chesnais","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0545","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.clml.2015.07.645","article-title":"Treatment of patients with myelodysplastic syndrome with lenalidomide in clinical routine in Austria","volume":"15","author":"Aschauer","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2022.100971_bb0550","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1053\/j.seminoncol.2011.04.015","article-title":"Role of lenalidomide in the treatment of myelodysplastic syndromes","volume":"38","author":"Komrokji","year":"2011","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2022.100971_bb0555","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.leukres.2012.11.017","article-title":"Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial","volume":"37","author":"Revicki","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2022.100971_bb0560","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1101\/gr.225128.117","article-title":"Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations","volume":"28","author":"Shah","year":"2018","journal-title":"Genome Res"},{"key":"10.1016\/j.blre.2022.100971_bb0565","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fonc.2019.01048","article-title":"Long non-coding RNAs in myeloid malignancies","volume":"9","author":"Zimta","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2022.100971_bb0570","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3389\/fphar.2020.01044","article-title":"Targeting the microenvironment in MDS: the final frontier","volume":"11","author":"Teodorescu","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.blre.2022.100971_bb0575","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2014-04-522136","article-title":"Recent developments in myelodysplastic syndromes","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0580","first-page":"1","article-title":"Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes","volume":"6","author":"Abou Zahr","year":"2015","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2022.100971_bb0585","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2015-07-567958","article-title":"The novel mechanism of lenalidomide activity","volume":"126","author":"Fink","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0595","doi-asserted-by":"crossref","first-page":"12974","DOI":"10.1073\/pnas.0811267106","article-title":"A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide","volume":"106","author":"Wei","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2022.100971_bb0600","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2006.10.035","article-title":"Role for the PP2A\/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis","volume":"127","author":"Margolis","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.blre.2022.100971_bb0605","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0610","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.blre.2022.100971_bb0615","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.blre.2022.100971_bb0620","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm.4127","article-title":"A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes","volume":"22","author":"Fang","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2022.100971_bb0625","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2165\/00003495-200767130-00005","article-title":"Lenalidomide in myelodysplastic syndrome and multiple myeloma","volume":"67","author":"Shah","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2022.100971_bb0630","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.exphem.2020.09.196","article-title":"Mechanisms of lenalidomide sensitivity and resistance","volume":"91","author":"Martinez-H\u00f8yer","year":"2020","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2022.100971_bb0635","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"J\u00e4dersten","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.blre.2022.100971_bb0640","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1309\/AJCPHC85DGAXZDBE","article-title":"p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed\/refractory multiple myeloma treated with lenalidomide","volume":"137","author":"Chen","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.blre.2022.100971_bb0645","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41556-020-0497-9","article-title":"Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome","volume":"22","author":"Martinez-H\u00f8yer","year":"2020","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0650","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.clml.2018.07.293","article-title":"SOHO state of the art and next questions: management of myelodysplastic syndromes with deletion 5q","volume":"18","author":"Talati","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2022.100971_bb0655","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0660","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1182\/blood.2020007081","article-title":"Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma","volume":"137","author":"Gooding","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0665","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/leu.2013.59","article-title":"A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low\/int-1 risk MDS without del(5q)","volume":"27","author":"Sardnal","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100971_bb0670","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1038\/s41375-021-01373-4","article-title":"Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs","volume":"35","author":"Jones","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100971_bb0675","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","article-title":"Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma","volume":"13","author":"Ng","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2022.100971_bb0680","author":"Celgene"},{"key":"10.1016\/j.blre.2022.100971_bb0685","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100971_bb0690","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2022.100971_bb0700","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2021-147812","volume":"138","author":"Richardson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0720","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1158\/1538-7445.AM2020-1963","article-title":"Abstract 1963: targeting hematological malignancies with two functionally and mechanistically distinct classes of cereblon mediated protein homeostatic modulators","volume":"80","author":"Chourasia","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2022.100971_bb0725","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2022.100971_bb0730","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1074-5521(97)90198-8","article-title":"Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin","volume":"4","author":"Griffith","year":"1997","journal-title":"Chem Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0735","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 ligase ligands for PROTACs: how they were found and how to discover new ones","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discov Adv Life Sci R D"},{"key":"10.1016\/j.blre.2022.100971_bb0745","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.bmc.2019.02.048","article-title":"Cereblon versus VHL: hijacking E3 ligases against each other using PROTACs","volume":"27","author":"Girardini","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.blre.2022.100971_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113749","article-title":"Developments of CRBN-based PROTACs as potential therapeutic agents","volume":"225","author":"Wang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.blre.2022.100971_bb0755","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220026","article-title":"CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition","volume":"14","author":"Meyer","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2022.100971_bb0760","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1182\/blood.2020006846","article-title":"Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0765","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.blre.2022.100971_bb0770","doi-asserted-by":"crossref","first-page":"17698","DOI":"10.18632\/oncotarget.4131","article-title":"BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells","volume":"6","author":"Coud\u00e9","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2022.100971_bb0775","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2013-01-478420","article-title":"Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762","volume":"123","author":"Chaidos","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0780","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/acs.jmedchem.6b01816","article-title":"Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression","volume":"61","author":"Zhou","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2022.100971_bb0785","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2022.100971_bb0790","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.blre.2022.100971_bb0795","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/leu.2014.106","article-title":"Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma","volume":"28","author":"Moros","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100971_bb0800","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113608","article-title":"Development of photocontrolled BRD4 PROTACs for tongue squamous cell carcinoma (TSCC)","volume":"222","author":"Li","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.blre.2022.100971_bb0810","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.blre.2022.100971_bb0815","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","article-title":"Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma","volume":"24","author":"Chapuy","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2022.100971_bb0820","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.blre.2022.100971_bb0825","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3324\/haematol.2018.201483","article-title":"Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations","volume":"104","author":"Lim","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2022.100971_bb0830","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41375-018-0044-x","article-title":"Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma","volume":"32","author":"Zhang","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2022.100971_bb0835","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bbrc.2019.11.007","article-title":"Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells","volume":"521","author":"Mu","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.blre.2022.100971_bb0840","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1021\/acs.orglett.9b01326","article-title":"Chemoselective synthesis of Lenalidomide-based PROTAC library using alkylation reaction","volume":"21","author":"Qiu","year":"2019","journal-title":"Org Lett"},{"key":"10.1016\/j.blre.2022.100971_bb0845","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2006-07-028829","article-title":"PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase","volume":"109","author":"Chan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0850","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.2741\/3051","article-title":"Protein tyrosine phosphatases in the JAK\/STAT pathway","volume":"13","author":"Xu","year":"2008","journal-title":"Front Biosci J Virtual Libr"},{"key":"10.1016\/j.blre.2022.100971_bb0855","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00774-013-0514-1","article-title":"IL-6 negatively regulates osteoblast differentiation through the SHP2\/MEK2 and SHP2\/Akt2 pathways in vitro","volume":"32","author":"Kaneshiro","year":"2014","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.blre.2022.100971_bb0860","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.exphem.2006.04.017","article-title":"Shp-2 heterozygous hematopoietic stem cells have deficient repopulating ability due to diminished self-renewal","volume":"34","author":"Chan","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.blre.2022.100971_bb0865","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2003-09-3287","article-title":"Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis","volume":"103","author":"Loh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0870","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","article-title":"Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of Cancer","volume":"63","author":"LaMarche","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2022.100971_bb0875","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.jmedchem.0c00471","article-title":"Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein","volume":"63","author":"Wang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2022.100971_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113341","article-title":"Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders","volume":"218","author":"Yang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.blre.2022.100971_bb0885","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton\u2019s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing","volume":"26","author":"de Gorter","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.blre.2022.100971_bb0890","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1084\/jem.191.10.1745","article-title":"Bruton\u2019s tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement","volume":"191","author":"Petro","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2022.100971_bb0895","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.blre.2022.100971_bb0900","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2022.100971_bb0905","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: beyond Ibrutinib","volume":"14","author":"Bond","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2022.100971_bb0910","doi-asserted-by":"crossref","first-page":"E1328","DOI":"10.3390\/cancers12051328","article-title":"Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas","volume":"12","author":"George","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2022.100971_bb0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114009","article-title":"Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib","volume":"229","author":"Ran","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.blre.2022.100971_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113820","article-title":"Discovery of novel BTK PROTACs for B-cell lymphomas","volume":"225","author":"Zhao","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.blre.2022.100971_bb0925","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res"},{"key":"10.1016\/j.blre.2022.100971_bb0930","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S Ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.blre.2022.100971_bb0935","author":"Nurix Therapeutics, Inc"},{"key":"10.1016\/j.blre.2022.100971_bb0940","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2022.100971_bb0945","author":"Dialectic Therapeutics, Inc"},{"key":"10.1016\/j.blre.2022.100971_bb0950","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2021-147473","article-title":"Nx-5948, a selective degrader of BTK with activity in preclinical models of hematologic and brain malignancies","volume":"138","author":"Robbins","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100971_bb0955","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2021-151125","article-title":"A first-in-class STAT3 degrader KT-333 in development for treatment of hematologic cancers","volume":"138","author":"Liu","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2022.100971_bb5000","article-title":"Kill Two Birds with One Stone: A Multifunctional Dual-Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome-Positive Leukemia","volume":"9","author":"Ma","year":"2022","journal-title":"Adv Sci (Weinh)"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:30:12Z","timestamp":1759437012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22000455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":177,"alternative-id":["S0268960X22000455"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.100971","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.100971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100971"}}